– WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse bioprocessing solutions for global clients -…